|
KMID : 1130620090050020053
|
|
Journal of Clinical Neurology
2009 Volume.5 No. 2 p.53 ~ p.64
|
|
|
Muscle-Specific Receptor Tyrosine Kinase Antibody Positive Myasthenia Gravis Current Status
|
|
Oh Shin-Joong
|
|
|
Abstract
|
|
|
|
Muscle-specific tyrosine-kinase-antibody-positive myasthenia gravis (MuSK-MG) has emerged as a distinct entity since 2001. This disease has been reported worldwide, but with varying rates among patients with generalized acetylcholine-receptor-antibody-negative MG. MuSK-MG was detected in approximately 37% of generalized acetylcholine receptor antibody-negative MG. MuSK-MG patients were predominantly female with more prominent facial and bulbar involvement and more frequent crises. Disease onset tended to be earlier. Patients tended to have a relatively poor edrophonium response but showed prominent decrement in the repetitive nerve stimulation test in the facial muscles. Patients were more likely to display poor tolerance of, or a lack of improvement with, anticholinesterase agents. Somewhat better response was observed with steroids and plasma exchange. Most were managed successfully with aggressive immunomodulatory therapies, although a higher proportion of MuSK-MG patients had a refractory course when compared with other forms of generalized MG. I present here an up-to-date overview on MuSK-MG based on our experience at the University of Alabama at Birmingham and the existing literature.
|
|
|
KEYWORD
|
|
|
myasthenia gravis, muscle-specific tyrosine-kinase-antibody, seronegative myasthenia gravis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
   
|